Zilebesiran Shows Potential in Lowering Blood Pressure in High-Risk Hypertensive Patients
Clinical trial data suggests that zilebesiran, an investigational RNA therapy, may help lower blood pressure in high-risk hypertensive patients, paving the way for new treatment options.
Recent clinical trial results reveal that a single subcutaneous dose of zilebesiran, an investigational RNA interference therapy, has the potential to reduce blood pressure in patients with uncontrolled hypertension and a high risk of cardiovascular disease. The phase II KARDIA-3 trial, conducted across five countries, focused on adult patients with established cardiovascular conditions or high risk factors, who were already on multiple antihypertensive medications but still had elevated blood pressure readings. The study analyzed the effects of zilebesiran at doses of 300 mg and 600 mg compared to placebo, observing changes over a three- to six-month period.
Results indicated a trend toward lower systolic blood pressure (SBP), with patients receiving 300 mg showing a mean reduction of 5 mmHg at three months, although this did not achieve statistical significance. Similar patterns were observed at six months, especially in 24-hour ambulatory blood pressure monitoring, where zilebesiran at both doses lowered SBP by approximately 5 to 7 mmHg compared to placebo. A notable post-hoc analysis showed greater blood pressure reduction in patients already on diuretics and with higher baseline SBP.
Safety assessments demonstrated that most adverse events were mild or moderate and transient, with serious adverse events being rare and comparable across groups. The findings suggest that while the primary endpoints did not reach statistical significance, the data support further investigation of zilebesiran in larger, more definitive phase III trials. As Dr. Neha Pagidipati emphasized, this study provides valuable insights that will inform future research aimed at improving hypertension management and cardiovascular outcomes.
High blood pressure remains a significant contributor to global mortality, and new treatments like zilebesiran could offer more effective options, especially for patients who struggle with achieving blood pressure control using current therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Establishing a Global Standard for Measuring Outcomes in Dengue Treatment Trials
A new global standard for measuring outcomes in dengue treatment trials has been published, aiming to unify clinical research methods and accelerate the development of effective therapies for the rapidly spreading disease.
Using Electronic Medical Records to Increase Fertility Preservation for Young Cancer Patients
Implementing a simple alert in electronic health records significantly increases fertility preservation referrals among young adult cancer patients, ensuring critical conversations happen before treatment begins.
Organ-Specific Inflammation Mimics Relapse in CAR T-Cell Therapy Remission
New research identifies organ-specific toxicity, LICATS, as a self-limiting side effect of CAR T-cell therapy in autoimmune diseases, aiding better diagnosis and management.
Innovative Focused Intervention Reduces Bias in Family Planning Clinics
A pioneering study finds targeted interventions in family planning clinics effectively reduce provider bias, enhancing contraceptive access for young women worldwide. This approach promotes respectful, inclusive reproductive health services across diverse settings.